Striking the Balance: Bipolar Disorder in the Perinatal Period
Focus · 2024-01 · 22 (1) · 3-15
DOI: 10.1176/appi.focus.20230020 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Focus, 2024-01. Verfasst von Caitlin Hasser und 4 weiteren Autor:innen. Beteiligte Einrichtung: Department of Psychiatry (Hasser, Knapp, Shah) and Department of Obstetrics and Gynecology (Knapp), School of Medicine, Oregon Health & Science Unive…. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 131 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
The authors reviewed the literature, published between 2018 and 2023, on treating bipolar disorder in the perinatal period in order to summarize current treatment perspectives. Mood episodes occur during pregnancy and there are high rates of both initial onset and recurrence in the postpartum period. Bipolar disorder itself is associated with higher risks of adverse pregnancy outcomes, including gestational hypertension, hemorrhage, cesarean delivery, and small for gestational age infants. A general principle of perinatal treatment includes maintaining psychiatric stability of the pregnant person while reducing medication exposure risk to the fetus. A variety of factors can compromise psychiatric stability, including rapid discontinuation of stabilizing medications, decreased efficacy due to physiologic changes of pregnancy, and exacerbation of underlying psychiatric illness. Psychosocial interventions include optimizing sleep, increasing support, and reducing stress. The American College of Obstetricians and Gynecologists recommends against discontinuing or withholding medications solely due to pregnancy or lactation status. Individualized treatment involves a discussion of the risks of undertreated bipolar disorder weighed against the risks of individual medication choice based on available evidence regarding congenital malformations, adverse neonatal and obstetrical events, and neurodevelopmental outcomes. Valproate is not a first-line treatment due to higher risks. Data are lacking on safety for many newer medications. The authors review current safety data regarding lithium, lamotrigine, and antipsychotics, which are the most commonly used treatments for managing bipolar disorder in the perinatal period. Due to physiologic changes during pregnancy, frequent therapeutic drug monitoring and dose adjustments are required.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Psychiatry (Hasser, Knapp, Shah) and Department of Obstetrics and Gynecology (Knapp), School of Medicine, Oregon Health & Science University, Portland, Oregon; Portland VA Health Care System, Portland, Ore…
Zitieren
APA
Hasser, C., Ameresekere, M., Girgis, C., Knapp, J., & Shah, R. (2024). Striking the Balance: Bipolar Disorder in the Perinatal Period. Focus, 22(1), 3-15. https://doi.org/10.1176/appi.focus.20230020
Vancouver
Hasser C, Ameresekere M, Girgis C, Knapp J, Shah R. Striking the Balance: Bipolar Disorder in the Perinatal Period. Focus. 2024;22(1):3-15. doi:10.1176/appi.focus.20230020
BibTeX
@article{Hasser2024,
author = {Hasser, Caitlin and Ameresekere, Maithri and Girgis, Christina and Knapp, Jacquelyn and Shah, Riva},
title = {Striking the Balance: Bipolar Disorder in the Perinatal Period},
journal = {Focus},
year = {2024},
volume = {22},
number = {1},
pages = {3--15},
doi = {10.1176/appi.focus.20230020}
}
EUVIMED